{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:54:56Z","timestamp":1789685696122,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ijcard.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T02:57:03Z","timestamp":1675911423000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis"],"prefix":"10.1016","volume":"377","author":[{"given":"Ahmed M.","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.H.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Obaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Halcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.02.004_bb0010","series-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD diseases of the European Society of Cardiology (ESC) and the. 2020","first-page":"255","author":"Task","year":"2019"},{"issue":"19","key":"10.1016\/j.ijcard.2023.02.004_bb0015","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Eliaschewitz","year":"2016","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol [Internet]"},{"issue":"39","key":"10.1016\/j.ijcard.2023.02.004_bb0025","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2023.02.004_bb0035","series-title":"Fewer people in Wales dying from heart disease \u2013 new report","year":"2022"},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6947-9-3","article-title":"The SAIL databank: Linking multiple health and social care datasets","volume":"9","author":"Lyons","year":"2009","journal-title":"BMC Med Inform Decis Mak"},{"issue":"8","key":"10.1016\/j.ijcard.2023.02.004_bb0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/2047487320914115","article-title":"Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: a population-level observational cohort study","volume":"28","author":"Harris","year":"2021","journal-title":"Eur J Prev Cardiol."},{"issue":"9753","key":"10.1016\/j.ijcard.2023.02.004_bb0050","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019\u2019 C","year":"2010","journal-title":"Lancet (London, England)."},{"issue":"9976","key":"10.1016\/j.ijcard.2023.02.004_bb0055","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2023.02.004_bb0060","first-page":"2551","article-title":"Prognostic impact of achieving LDL cholesterol guidelines-recommended target in secondary prevention: a real-world study","volume":"42","author":"Casula","year":"2021","journal-title":"Eur Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01164-8","article-title":"Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10.1016\/j.ijcard.2023.02.004_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/ijem.IJEM_532_20","article-title":"Compliance of secondary prevention strategies in coronary artery disease patients with and without diabetes mellitus - a cross-sectional analytical survey from Kerala, India","volume":"25","author":"Sudevan","year":"2021","journal-title":"Indian J Endocrinol Metab."},{"issue":"13","key":"10.1016\/j.ijcard.2023.02.004_bb0075","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.117.027252","article-title":"Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus","volume":"136","author":"Pagidipati","year":"2017","journal-title":"Circulation."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2023.02.004_bb0080","article-title":"Application of the 2018 cholesterol guideline for secondary prevention in very high-risk patients with atherosclerotic cardiovascular disease in the United States","volume":"12","author":"Shin","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"Supplement 1","key":"10.1016\/j.ijcard.2023.02.004_bb0085","first-page":"868","article-title":"Better adherence to lipid lowering guidelines in secondary prevention may result in substantial reduction in cardiovascular events","volume":"40","author":"Odesjo","year":"2019","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ijcard.2023.02.004_bb0090","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.clinthera.2008.12.003","article-title":"Long-term persistence with statin therapy: a nationwide register study in Finland","volume":"30 pt 2(PART 2)","author":"Helin-Salmivaara","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.ijcard.2023.02.004_bb0095","first-page":"353","article-title":"Impact of statin related media coverage on use of statins: Interrupted time series analysis with UK primary care data","author":"Matthews","year":"2016","journal-title":"BMJ (Online)"},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-8227(03)00065-2","article-title":"Underuse of evidence-based treatment modalities in diabetic patients with non-ST elevation acute coronary syndrome. A prospective nation wide study on acute coronary syndrome (FINACS)","volume":"61","author":"Vikman","year":"2003","journal-title":"Diabetes Res Clin Pract."},{"issue":"7","key":"10.1016\/j.ijcard.2023.02.004_bb0105","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","article-title":"Can statins cause chronic low-grade myopathy?","volume":"137","author":"Grundy","year":"2002","journal-title":"Ann Intern Med."},{"issue":"12","key":"10.1016\/j.ijcard.2023.02.004_bb0110","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.ijcard.2023.02.004_bb0115","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.ijcard.2023.02.004_bb0120","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no Treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/ehjqcco\/qcaa016","article-title":"Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC\/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: Nationwide cohort study, 2013-17","volume":"7","author":"Allahyari","year":"2021","journal-title":"Eur Hear J - Qual Care Clin Outcomes."},{"issue":"11","key":"10.1016\/j.ijcard.2023.02.004_bb0130","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"39","key":"10.1016\/j.ijcard.2023.02.004_bb0135","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2023.02.004_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004157","article-title":"Glycemic control status after percutaneous coronary intervention and long-term clinical outcomes in patients with type 2 diabetes mellitus","volume":"10","author":"Hwang","year":"2017","journal-title":"Circ Cardiovasc Interv."},{"issue":"6","key":"10.1016\/j.ijcard.2023.02.004_bb0145","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3904\/kjim.2020.694","article-title":"Long-term effects of the mean hemoglobin A1c levels after percutaneous coronary intervention in patients with diabetes","volume":"36","author":"Bae","year":"2021","journal-title":"Korean J Intern Med."},{"issue":"4","key":"10.1016\/j.ijcard.2023.02.004_bb0150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/CIRCINTERVENTIONS.113.001107","article-title":"Association of glycemic control with mortality in patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"7","author":"Sharma","year":"2014","journal-title":"Circ Cardiovasc Interv."},{"issue":"4","key":"10.1016\/j.ijcard.2023.02.004_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijcard.2023.02.004_bb0160","series-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","first-page":"101","volume":"vol. 54","author":"Nordisk","year":"2016"},{"issue":"9","key":"10.1016\/j.ijcard.2023.02.004_bb0165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail."},{"key":"10.1016\/j.ijcard.2023.02.004_bb0170","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ijcard.2023.02.004_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/dom.13877","article-title":"Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study","volume":"22","author":"Bang","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"Supplement_1","key":"10.1016\/j.ijcard.2023.02.004_bb0180","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"Association AD","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2023.02.004_bb0185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.diabres.2019.05.013","article-title":"CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle","volume":"153","author":"Schernthaner","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ijcard.2023.02.004_bb0190","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"191","author":"Schernthaner","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-022-01495-8","article-title":"Physicians\u2019 misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes","volume":"21","author":"Morieri","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement 2","key":"10.1016\/j.ijcard.2023.02.004_bb0200","first-page":"19","article-title":"Secondary prevention of cardiovascular disease needs improvement in men and women, with and without diabetes: the Tromso Study 2015-16","volume":"28","author":"Hopstock","year":"2019","journal-title":"Nor Epidemiol"},{"issue":"11","key":"10.1016\/j.ijcard.2023.02.004_bb0205","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1210\/jc.2019-00168","article-title":"Relationship between number of multiple risk factors and coronary artery disease risk with and without diabetes mellitus","volume":"104","author":"Yamada-Harada","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ijcard.2023.02.004_bb0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","article-title":"Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German\/Austrian DPV-multicenter analysis","volume":"15","author":"Bohn","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.ijcard.2023.02.004_bb0215","article-title":"Current status in achievement of glycaemic, lipid and blood pressure goals in type 2 diabetic patients with coronary artery disease","volume":"50","author":"Fau","year":"2009","journal-title":"Hell J Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2023.02.004_bb0220","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/hrt.2010.213710","article-title":"Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe","volume":"97","author":"Cacoub","year":"2011","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.ijcard.2023.02.004_bb0225","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/eurjpc\/zwab050","article-title":"Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the Troms\u00f8 Study 2015\u201316","volume":"29","author":"Hopstock","year":"2022","journal-title":"Eur J Prev Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2023.02.004_bb0230","first-page":"901","article-title":"Impact of the 2013 cholesterol guideline on patterns of lipid-lowering treatment in patients with atherosclerotic cardiovascular disease or diabetes after 1 year","volume":"22","author":"Tran","year":"2016","journal-title":"J Manag Care Spec Pharm."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323001791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323001791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:00:44Z","timestamp":1759093244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323001791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":45,"alternative-id":["S0167527323001791"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.02.004","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}